Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 542

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Open access
Blank, Christian U., Lucas, Minke W., Scolyer, Richard A., van de Wiel, Bart A., Menzies, Alexander M., Lopez-Yurda, Marta, Hoeijmakers, Lotte L., Saw, Robyn P.M., Lijnsvelt, Judith M., Maher, Nigel G., Pulleman, Saskia M., Gonzalez, Maria, Torres Acosta, Alejandro, van Houdt, Winan J., Lo, Serigne N., Kuijpers, Anke M.J., Spillane, Andrew, Klop, W. Martin C., Pennington, Thomas E., Zuur, Charlotte L., Shannon, Kerwin F., Seinstra, Beatrijs A., Rawson, Robert V., Haanen, John B.A.G., Ch’ng, Sydney, Naipal, Kishan A.T., Stretch, Jonathan, van Thienen, Johannes V., Rtshiladze, Michael A., Wilgenhof, Sofie, Kapoor, Rony, Meerveld-Eggink, Aafke, Grijpink-Ongering, Lindsay G., van Akkooi, Alexander C.J., Reijers, Irene L.M., Gyorki, David E., Grünhagen, Dirk J., Speetjens, Frank M., Vliek, Sonja B., Placzke, Joanna, Spain, Lavinia, Stassen, Robert C., Amini-Adle, Mona, Lebbé, Céleste, Faries, Mark B., Robert, Caroline, Ascierto, Paolo A., van Rijn, Rozemarijn, van den Berkmortel, Franchette W.P.J., Piersma, Djura, van der Westhuizen, Andre, Vreugdenhil, Gerard, Aarts, Maureen J.B., Stevense-den Boer, Marion A.M., Atkinson, Victoria, Khattak, Muhammad, Andrews, Miles C., van den Eertwegh, Alfons J.M., Boers-Sonderen, Marye J., Hospers, Geke A.P., Carlino, Matteo S., de Groot, Jan-Willem B., Kapiteijn, Ellen, Suijkerbuijk, Karijn P.M., Rutkowski, Piotr, Sandhu, Shahneen, van der Veldt, Astrid A.M., Long, Georgina V.·2024·New England Journal of Medicine

Abstract

BACKGROUND: In phase 1-2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy. METHODS: In this phase 3 trial, we randomly assigned patients with resectable, macroscopic stage III melanoma to two cycles of neoadjuvant ipilimumab plus nivolumab followed by surgery or surgery followed by 12 cycles of adjuvant nivolumab. Only patients in the neoadjuvant group with a partial response or nonresponse received adjuvant treatment. The primary end point was event-free survival. RESULTS: A total of 423 patients underwent randomization. At a median follow-up of 9.9 months, the estimated 12-month event-free survival was 83.7% (99.9% confidence interval [CI], 73.8 to 94.8) in the neoadjuvant group and 57.2% (99.9% CI, 45.1 to 72.7) in the adjuvant group. The difference in restricted mean survival time was 8.00 months (99.9% CI, 4.94 to 11.05; P<0.001; hazard ratio for progression, recurrence, or death, 0.32; 99.9% CI, 0.15 to 0.66). In the neoadjuvant group, 59.0% of patients had a major pathological response, 8.0% had a partial response, 26.4% had a nonresponse (>50% residual viable tumor), and 2.4% had progression; in 4.2%, surgery had not yet been performed or was omitted. The estimated 12-month recurrence-free survival was 95.1% in patients in the neoadjuvant group who had a major pathological response, 76.1% among those with a partial response, and 57.0% among those with a nonresponse. Adverse events of grade 3 or higher that were related to systemic treatment occurred in 29.7% of patients in the neoadjuvant group and in 14.7% in the adjuvant group. CONCLUSIONS: Among patients with resectable, macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab followed by surgery and response-driven adjuvant therapy resulted in longer event-free survival than surgery followed by adjuvant nivolumab. (Funded by Bristol Myers Squibb and others; NADINA ClinicalTrials.gov number, NCT04949113.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2402604

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 542

Metadata

Authors
Blank, C. U., Lucas, M. W., Scolyer, R. A., van de Wiel, B. A., Menzies, A. M., Lopez-Yurda, M., Hoeijmakers, L. L., Saw, R. P. M., Lijnsvelt, J. M., Maher, N. G., Pulleman, S. M., Gonzalez, M., Torres Acosta, A., van Houdt, W. J., Lo, S. N., Kuijpers, A. M. J., Spillane, A., Klop, W. M. C., Pennington, T. E., Zuur, C. L., Shannon, K. F., Seinstra, B. A., Rawson, R. V., Haanen, J. B. A. G., Ch’ng, S., Naipal, K. A. T., Stretch, J., van Thienen, J. V., Rtshiladze, M. A., Wilgenhof, S., Kapoor, R., Meerveld-Eggink, A., Grijpink-Ongering, L. G., van Akkooi, A. C. J., Reijers, I. L. M., Gyorki, D. E., Grünhagen, D. J., Speetjens, F. M., Vliek, S. B., Placzke, J., Spain, L., Stassen, R. C., Amini-Adle, M., Lebbé, C., Faries, M. B., Robert, C., Ascierto, P. A., van Rijn, R., van den Berkmortel, F. W. P. J., Piersma, D., van der Westhuizen, A., Vreugdenhil, G., Aarts, M. J. B., Stevense-den Boer, M. A. M., Atkinson, V., Khattak, M., Andrews, M. C., van den Eertwegh, A. J. M., Boers-Sonderen, M. J., Hospers, G. A. P., Carlino, M. S., de Groot, J.-W. B., Kapiteijn, E., Suijkerbuijk, K. P. M., Rutkowski, P., Sandhu, S., van der Veldt, A. A. M., & Long, G. V.
Venue
New England Journal of Medicine
Published
2024-11-07
Volume
391
Issue
18
Pages
1696-1708
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4399274678
Cited by
542
References
28
FWCI
83.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. https://app.cochat.ai/papers/10.1056/nejmoa2402604
The paper
Blank, C. U., Lucas, M. W., Scolyer, R. A., van de Wiel, B. A., Menzies, A. M., Lopez-Yurda, M., Hoeijmakers, L. L., Saw, R. P. M., Lijnsvelt, J. M., Maher, N. G., Pulleman, S. M., Gonzalez, M., Torres Acosta, A., van Houdt, W. J., Lo, S. N., Kuijpers, A. M. J., Spillane, A., Klop, W. M. C., Pennington, T. E., . . . Long, G. V. (2024). Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2402604

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.